Reports 3Q revenue $51.3M, consensus $50.72M. Reports 3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q 2022;3Q 2023 Endocrine BU net revenues of $18M; Afrezza net revenues +24% vs. 3Q 2022…”We had another strong quarter of revenue growth with total revenues exceeding $51 million,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “With the continued success of Tyvaso DPI(R), we believe we will continue to have the ability to execute our commercial operating plan and fund our pipeline development efforts.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MNKD:
- MannKind options imply 9.3% move in share price post-earnings
- MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
- MannKind completes enrollment in Phase 4 trial in diabetes
- MNKD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
Questions or Comments about the article? Write to editor@tipranks.com